Clinical Trials Logo

Relapsed Hodgkin Lymphoma clinical trials

View clinical trials related to Relapsed Hodgkin Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04134325 Recruiting - Clinical trials for Refractory Hodgkin Lymphoma

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Start date: September 1, 2019
Phase: Early Phase 1
Study type: Interventional

LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL).

NCT ID: NCT04052997 Completed - Clinical trials for Refractory Hodgkin Lymphoma

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Start date: September 13, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).

NCT ID: NCT02875067 Terminated - Clinical trials for Relapsed Non-Hodgkin Lymphoma

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Start date: August 29, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is to assess the safety & efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.